Skip to content

Wells Pharma of Houston, LLC. v. Zyla Life Sciences, LLC.

Pending petition

Docket No. Op. BelowArgument Opinion Vote Author Term
25-257 5th Cir. TBD TBD TBD TBD TBD

Issue: Whether the Federal Food, Drug, and Cosmetic Act preempts private state-law unfair competition and consumer protection claims premised on the marketing of compounded drugs without premarket approval.

DateProceedings and Orders (key to color coding)
09/02/2025Petition for a writ of certiorari filed. (Response due October 6, 2025)
09/11/2025Waiver of right of respondent Zyla Life Sciences, L.L.C. to respond filed.
09/17/2025DISTRIBUTED for Conference of 10/10/2025.
09/25/2025Response Requested. (Due October 27, 2025)
10/06/2025Brief amicus curiae of Americans for Access to Compounded Medication filed.
10/16/2025Motion to extend the time to file a response from October 27, 2025 to November 17, 2025, submitted to The Clerk.
10/20/2025Motion to extend the time to file a response is granted and the time is extended to and including November 17, 2025.
10/27/2025Brief amicus curiae of Outsourcing Facilities Association filed.
11/17/2025Brief of respondent Zyla Life Sciences, L.L.C. in opposition filed.
11/25/2025Reply of petitioner Wells Pharma of Houston, L.L.C. filed.
12/03/2025DISTRIBUTED for Conference of 1/9/2026.
01/12/2026The Solicitor General is invited to file a brief in this case expressing the views of the United States.